Get the Stockscreener App
14.23
2.01%
0.28
After Hours:
14.23
Edgewise Therapeutics Inc stock is traded at $14.23, with a volume of 1.06M.
It is up +2.01% in the last 24 hours and up +8.05% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$13.95
Open:
$14.38
24h Volume:
1.06M
Relative Volume:
1.19
Market Cap:
$1.50B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-9.1996
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
-1.11%
1M Performance:
+8.05%
6M Performance:
-49.18%
1Y Performance:
-16.49%
1-Day Range:
$14.12
$15.33
1-Week Range:
$13.78
$15.33
52-Week Range:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
14.23 | 1.47B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Raymond James Initiates Edgewise Therapeutics at Strong Buy - MarketScreener
Skandinaviska Enskilda Banken AB publ Takes $827,000 Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
When is the best time to buy Edgewise Therapeutics Inc. stockEarnings Report Summary with Market Impact - Newser
How sentiment analysis helps forecast Edgewise Therapeutics Inc.Weekly Price Target Forecast and Alerts - Newser
What makes Edgewise Therapeutics Inc. stock price move sharplySector Rotation Outlook With Historical Summary - Newser
Heatmap analysis for Edgewise Therapeutics Inc. and competitorsFundamental Forecast for Undervalued Stocks - Newser
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating By Investing.com - Investing.com Canada
Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating - Investing.com
Edgewise Therapeutics, Inc. (EWTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why Edgewise Therapeutics Inc. stock attracts strong analyst attentionReal-Time Setup Summary with ROI Focus - Newser
Is Edgewise Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSector-Wise Equity Performance Trend Forecast - Newser
How Interest Rate Changes Impact Edgewise Therapeutics Inc. Stock PerformanceWeekly Portfolio Update with ROI Focus - Newser
Edgewise Therapeutics Inc. Could See a Relief Rally From SupportChart Breakout Buy Signal Detection Confirmed - beatles.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - FinancialContent
Bronstein, Gewirtz & Grossman, LLC Is Investigating Edgewise Therapeutics, Inc. (EWTX) And Encourages Investors to Connect - ACCESS Newswire
Why is Edgewise Therapeutics Inc. stock attracting strong analyst attentionCapital growth strategies that work - jammulinksnews.com
What is the dividend policy of Edgewise Therapeutics Inc. stockMarket-leading growth rates - jammulinksnews.com
How sentiment analysis helps forecast Edgewise Therapeutics Inc. Momentum Trading Guide with Safety Limits - Newser
What catalysts could drive Edgewise Therapeutics Inc. stock higher in 2025Game-changing returns - jammulinksnews.com
What are the latest earnings results for Edgewise Therapeutics Inc.Breakthrough profit margins - jammulinksnews.com
What are the technical indicators suggesting about Edgewise Therapeutics Inc.Invest confidently with professional market insights - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Edgewise Therapeutics, Inc. (EWTX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - MarketScreener
What are Edgewise Therapeutics Inc. company’s key revenue driversDiscover stocks with massive upside potential - jammulinksnews.com
Sectors Driving Future Growth for Edgewise Therapeutics Inc. StockFree Access to Group - Newser
Edgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder Drug - MSN
Edgewise Therapeutics, Inc. (EWTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What analysts say about Edgewise Therapeutics Inc. stockRapidly growing investment returns - PrintWeekIndia
Jennison Associates LLC Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Readystate Asset Management LP Boosts Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
What drives Edgewise Therapeutics Inc. stock priceRapid wealth accumulation - Autocar Professional
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Edgewise Therapeutics, Inc. (EWTX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Edgewise Therapeutics Inc. Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
Becker Muscular Dystrophy Pipeline 2025: Key Companies, MOA, - openPR.com
BlackRock, Inc. Reduces Stake in Edgewise Therapeutics Inc. - GuruFocus
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by Arizona State Retirement System - Defense World
Is Edgewise Therapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Edgewise Therapeutics, Inc. (EWTX) And Encourages Investors to Reach Out - ACCESS Newswire
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):